AI Article Synopsis
- The 2019 guidelines recommend women with an unsatisfactory Pap test and negative HPV test undergo repeat screening in 2 to 4 months, as a negative HPV result may not be definitive due to potential sample issues.* -
- Our study analyzed data from 1,496 cases with unsatisfactory Pap tests and HPV cotests, finding that a negative HPV test was very predictive of the absence of high-grade lesions.* -
- Despite a low compliance rate for follow-up screenings (45.1%), the results suggest that women with an unsatisfactory Pap test and negative HPV results may not need to return for repeat testing as soon as previously recommended.*
Article Abstract
Objectives: The 2019 American Society of Colposcopy and Cervical Pathology management guidelines recommend that patients with an unsatisfactory Papanicolaou (Pap) test (UPT) and negative human papillomavirus (HPV) cotest undergo repeat age-based screening in 2 to 4 months. The rationale is that a negative HPV test in the setting of an UPT may reflect an inadequate sample and therefore should not be interpreted as truly "negative." For patients 25 years and older who are cotested, if HPV is positive for the 16 or 18 genotypes, direct referral for colposcopy is recommended. Our study aimed to determine if a negative HPV cotest result is predictive of the absence of a high-grade squamous intraepithelial lesion (HSIL) and whether these patients may be called back for repeat testing at an interval longer than 2 to 4 months.
Methods: Follow-up cervical cytology and biopsy results in women with UPT and HPV cotests from January 2017 to December 2021 were collected. Original UPT and HPV cotest results were correlated with the follow-up Pap and biopsy results.
Results: There were 1,496 (2.28%) UPT cases out of 65,641 total Pap tests. Among the 1,496 UPT cases, 1,010 (67.5%) had HPV cotesting; 676 (45.1%) were followed by repeat Pap or biopsy within 4 months and 850 (56.8%) within 12 months. The total follow-up rate was 81%, with a range of 3 days to 36 months. The HSIL rate in HPV-positive cases was 5.7% (3/53) vs 0.4% (2/539) (P = .006) in HPV-negative cases. In UPT, HPV cotesting showed negative predictive values for low-grade and high-grade squamous intraepithelial lesion detection of 98.5% and 99.6%, respectively, while positive predictive values were 19% and 5.7%.
Conclusions: A negative HPV cotest in individuals with UPT predicted the lack of HSIL in our study. Compliance with the recommended follow-up time of 2 to 4 months for women with UPT was low (45.1%). Our study suggests that women with UPT and negative HPV cotest may be safely called back at an interval longer than 4 months.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ajcp/aqad026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
DNA methylation analysis on anal swabs for anal cancer screening in people living with HIV.
J Infect Dis
December 2024
Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of Pathology, Boelelaan 1117, Amsterdam, The Netherlands.
Introduction: High-resolution anoscopy (HRA) to prevent anal cancer is complex and screening capacity is limited. Previously, we showed that DNA methylation analysis of anal high-grade squamous intraepithelial lesions (HSIL) biopsies can distinguish between HSIL with an increased cancer risk, and HSIL with a low cancer risk, in which treatment may be safely withheld. Here, we assessed the performance of methylation analysis in anal swabs to identify patients with underlying HSIL with an increased cancer risk.
View Article and Find Full Text PDF2024 Hong Kong College of Obstetricians and Gynaecologists Guidelines for cervical cancer prevention and screening.
Hong Kong Med J
December 2024
Department of Obstetrics and Gynaecology, The University of Hong Kong, Hong Kong SAR, China.
Primary prevention of cervical cancer is best achieved by vaccinating girls with a prophylactic human papillomavirus (HPV) vaccine. Despite the high efficacy of such vaccines, cervical cancer screening remains necessary because current vaccines do not offer full protection. Secondary prevention via cervical screening should target all women from age 25 years or at the onset of sexual activity, whichever occurs later, until age 64 years.
View Article and Find Full Text PDFHPV E6/E7 mRNA screening alone can be used as a screening method for cervical cancer in premenopausal women in China: A retrospective study.
Int J Gynaecol Obstet
November 2024
Department of Gynecology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
Background: This study aimed to assess the value of a HPV E6/E7 mRNA assay (Aptima® HPV [AHPV]) for primary cervical cancer screening combined with menopausal status.
Methods: A total of 16 917 women underwent AHPV testing and had complete histopathological results at the Affiliated Hospital of Jining Medical University China between January 1, 2017 and March 31, 2022. We evaluated the performance of different screening strategies and combined strategies, as well as evaluations of different menopausal states.
Retrospective analysis of HPV infection: Cotesting and HPV genotyping in cervical cancer screening within a large academic health care system.
Cancer Cytopathol
November 2024
Department of Pathology and Laboratory Medicine, Emory University Hospital, Emory University School of Medicine, Atlanta, Georgia, USA.
Background: In 2019, the American Society for Colposcopy and Cervical Pathology introduced fundamental shifts toward "risk-based" guidelines, with human papillomavirus (HPV) genotyping as a principal test for investigating squamous intraepithelial lesions. This study aims to provide practice-based evidence and supplement the updated guidelines by investigating HPV demographic distribution and uncovering the pathological features of high-grade squamous intraepithelial lesions (HSILs) caused by high-risk HPV (hrHPV) subtypes.
Methods: Patients who underwent Papanicolaou screening and HPV testing in two hospital systems over the course of 4 years were recruited.
Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters.
Expert Rev Anticancer Ther
November 2024
Department of Gynecology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Background: We aimed to develop a nomogram to predict abnormal follow-up results of co-testing for cytology and human papillomavirus (HPV) in cervical intraepithelial neoplasia (CIN) patients after conization.
Research Design And Methods: Two hundred sixty-three patients initially diagnosed as CIN2+ were recruited. Data on immunohistochemical (IHC) staining scores, along with demographic and clinical information were collected.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!